• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西版 CHOP INTEND 量表:跨文化调适与验证。

Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation.

机构信息

Instituto de Medicina Integral Professor Fernando Figueira, Pós-graduação em Saúde Integral, Recife PE, Brazil.

Hospital Otávio de Freitas, Departamento de Reabilitação, Recife PE, Brazil.

出版信息

Arq Neuropsiquiatr. 2023 Sep;81(9):816-824. doi: 10.1055/s-0043-1772832. Epub 2023 Oct 4.

DOI:10.1055/s-0043-1772832
PMID:37793404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10550346/
Abstract

BACKGROUND

Spinal muscular atrophy (SMA) is a rare genetic disease that causes progressive muscle weakness and impacts motor function. The type I is the most severe presentation and affects infants before 6 months old. In addition, the instruments available for assessing motor function have limitations when applied to infants with neuromuscular diseases and significant muscle weakness.

OBJECTIVE

To translate, cross-culturally adapt, and validate the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) to Brazilian Portuguese.

METHODS

The present study comprised the translation, synthesis of translations, backtranslation, consolidation by a committee of experts, and test of the final version of the CHOP INTEND in 13 patients with SMA type I. We also assessed the content validity and reliability of the translated version.

RESULTS

The scale was translated considering semantic, structural, idiomatic, and cultural aspects. All agreement rates were > 0.8, the overall content validity index of the instrument was 0.98, and inter-rater reliability using the intraclass correlation coefficient was 0.998.

CONCLUSION

The Brazilian version of the CHOP INTEND met semantic and technical equivalence criteria with the original version and was valid and reliable for patients with SMA type I.

摘要

背景

脊髓性肌萎缩症(SMA)是一种罕见的遗传性疾病,会导致进行性肌肉无力并影响运动功能。I 型是最严重的表现,会影响 6 个月以下的婴儿。此外,用于评估运动功能的仪器在应用于患有神经肌肉疾病和严重肌肉无力的婴儿时存在局限性。

目的

将费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND)翻译成巴西葡萄牙语,并进行跨文化适应性验证。

方法

本研究包括翻译、翻译合成、回译、专家委员会的整合以及对 13 名 I 型 SMA 患者的 CHOP INTEND 最终版本的测试。我们还评估了翻译版本的内容有效性和可靠性。

结果

该量表在考虑语义、结构、习惯用法和文化方面进行了翻译。所有一致性率均>0.8,仪器的总体内容有效性指数为 0.98,使用组内相关系数的评分者间可靠性为 0.998。

结论

CHOP INTEND 的巴西版本与原始版本在语义和技术等效性方面均符合标准,并且对 I 型 SMA 患者有效且可靠。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/513e/10550346/4fefc0624b5b/10-1055-s-0043-1772832-i220302-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/513e/10550346/4fefc0624b5b/10-1055-s-0043-1772832-i220302-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/513e/10550346/4fefc0624b5b/10-1055-s-0043-1772832-i220302-1.jpg

相似文献

1
Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation.巴西版 CHOP INTEND 量表:跨文化调适与验证。
Arq Neuropsiquiatr. 2023 Sep;81(9):816-824. doi: 10.1055/s-0043-1772832. Epub 2023 Oct 4.
2
Enhancing the cross-cultural adaptation and validation process: linguistic and psychometric testing of the Brazilian-Portuguese version of a self-report measure for dry eye.增强跨文化适应和验证过程:对一种自我报告干眼测量工具的巴西葡萄牙语版本进行语言和心理计量学测试。
J Clin Epidemiol. 2015 Apr;68(4):370-8. doi: 10.1016/j.jclinepi.2014.07.009. Epub 2014 Dec 17.
3
The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND):测试的开发和可靠性。
Neuromuscul Disord. 2010 Mar;20(3):155-61. doi: 10.1016/j.nmd.2009.11.014. Epub 2010 Jan 13.
4
Brazilian version of the Pediatric Functional Status Scale: translation and cross-cultural adaptation.《儿童功能状态量表》巴西版本:翻译与跨文化调适
Rev Bras Ter Intensiva. 2018 Jul-Sept;30(3):301-307. doi: 10.5935/0103-507X.20180043. Epub 2018 Sep 3.
5
Brazilian version of the Hammersmith Functional Motor Scale Expanded: cross-cultural adaptation and validation.巴西版汉密尔顿运动功能量表扩展版:跨文化调适与验证。
Arq Neuropsiquiatr. 2024 Jul;82(7):1-7. doi: 10.1055/s-0044-1788587. Epub 2024 Jul 29.
6
A Cross-Cultural Adaptation and Content Validity of COMFORTneo Scale into Brazilian Portuguese.COMFORTneo 量表的跨文化调适和内容效度验证到巴西葡萄牙语。
J Pain Symptom Manage. 2022 Dec;64(6):e323-e330. doi: 10.1016/j.jpainsymman.2022.08.006. Epub 2022 Aug 17.
7
Translation and cross-cultural adaptation of the Thyroidectomy-Related Voice Questionnaire (TVQ) to Brazilian Portuguese.甲状腺切除相关嗓音问卷(TVQ)的翻译及跨文化调适至巴西葡萄牙语。
Codas. 2020 Nov 9;32(5):e20190150. doi: 10.1590/2317-1782/20202019150. eCollection 2020.
8
Hospital emergency suitability protocol: translation and adaptation to the Brazilian culture.医院急诊适宜性协议:翻译和适应巴西文化。
Rev Gaucha Enferm. 2022 Aug 1;43:e20210183. doi: 10.1590/1983-1447.2022.20210183.en. eCollection 2022.
9
Symptom Status Questionnaire - Heart Failure - Brazilian Version: cross-cultural adaptation and content validation.症状状态问卷 - 心力衰竭 - 巴西版:跨文化调适和内容验证。
Heart Lung. 2021 Jul-Aug;50(4):525-531. doi: 10.1016/j.hrtlng.2021.02.010. Epub 2021 Apr 6.
10
Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.神经拓展脊髓性肌萎缩症婴儿生物标志物研究中运动功能测试的可靠性。
J Neuromuscul Dis. 2018;5(4):509-521. doi: 10.3233/JND-180327.

引用本文的文献

1
Brazilian Portuguese version of the revised upper-limb module: cross-cultural adaptation and validation.修订后的上肢模块的巴西葡萄牙语版本:跨文化调适与验证
Arq Neuropsiquiatr. 2025 Mar;83(3):1-6. doi: 10.1055/s-0045-1805072. Epub 2025 Mar 19.
2
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies.1 型脊肌萎缩症患者在接受疾病修正治疗前后的队列研究。
Arq Neuropsiquiatr. 2024 Nov;82(11):1-8. doi: 10.1055/s-0044-1791757. Epub 2024 Nov 6.
3
Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil.

本文引用的文献

1
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.脊髓性肌萎缩症(5q SMA)患儿管理的疾病修正治疗:新出现证据的更新。
Drug Des Devel Ther. 2022 Jun 16;16:1865-1883. doi: 10.2147/DDDT.S214174. eCollection 2022.
2
Spinal muscular atrophy: from rags to riches.脊髓性肌萎缩症:从一文不名到财源广进。
Neuromuscul Disord. 2021 Oct;31(10):998-1003. doi: 10.1016/j.nmd.2021.08.009.
3
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
脊髓性肌萎缩症的临床遗传学特征及对疾病修饰疗法的反应:来自巴西南部一个参考中心的真实世界经验。
J Pediatr (Rio J). 2025 Jan-Feb;101(1):38-45. doi: 10.1016/j.jped.2024.07.011. Epub 2024 Oct 16.
4
Integrated Approaches and Practical Recommendations in Patient Care Identified with 5q Spinal Muscular Atrophy through Newborn Screening.通过新生儿筛查鉴定 5q 型脊髓性肌萎缩症患者的综合治疗方法和实用建议。
Genes (Basel). 2024 Jun 29;15(7):858. doi: 10.3390/genes15070858.
5
Michigan appropriateness guide for intravenous catheters in pediatrics - miniMAGIC-Brasil: translation into Brazilian portuguese.密歇根儿科静脉导管适宜性指南 - miniMAGIC-Brasil:翻译为巴西葡萄牙语。
Rev Paul Pediatr. 2024 May 13;42:e2023159. doi: 10.1590/1984-0462/2024/42/2023159. eCollection 2024.
Risdiplam 治疗 1 型脊髓性肌萎缩症婴儿与历史对照。
N Engl J Med. 2021 Jul 29;385(5):427-435. doi: 10.1056/NEJMoa2102047.
4
Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments.基于无标记 3D 全身跟踪的 SMA 患儿定量运动测量与标准化运动评估高度相关。
J Neuromuscul Dis. 2022;9(1):121-128. doi: 10.3233/JND-200619.
5
Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment.脊髓性肌萎缩症:疾病修饰治疗时代功能性运动量表的应用
Child Neurol Open. 2021 Apr 27;8:2329048X211008725. doi: 10.1177/2329048X211008725. eCollection 2021 Jan-Dec.
6
A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.一种新的呼吸评分系统,用于评估接受 SMN 增强药物治疗的脊髓性肌萎缩症 1 型(SMA1)患儿的呼吸结局。
Neuromuscul Disord. 2021 Apr;31(4):300-309. doi: 10.1016/j.nmd.2021.01.008. Epub 2021 Jan 21.
7
Type I SMA "new natural history": long-term data in nusinersen-treated patients.I 型 SMA 的“新自然病史”:用 nusinersen 治疗的患者的长期数据。
Ann Clin Transl Neurol. 2021 Mar;8(3):548-557. doi: 10.1002/acn3.51276. Epub 2021 Feb 6.
8
Longitudinal natural history of type I spinal muscular atrophy: a critical review.I 型脊髓性肌萎缩症的纵向自然史:批判性回顾。
Orphanet J Rare Dis. 2020 Apr 5;15(1):84. doi: 10.1186/s13023-020-01356-1.
9
Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care.脊髓性肌萎缩症治疗进展——新表型、新挑战、新护理意义。
J Neuromuscul Dis. 2020;7(1):1-13. doi: 10.3233/JND-190424.
10
Evaluator Training and Reliability for SMA Global Nusinersen Trials1.脊髓性肌萎缩症全球依洛硫酸酯酶纳新酶临床试验 1 的评估者培训与可靠性
J Neuromuscul Dis. 2018;5(2):159-166. doi: 10.3233/JND-180301.